Evidence map›Paper›PMID 29253878›Full record

ArticlePloS one2017

Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid.

Kesava Asam, Agnieszka Staniszewski, Hong Zhang, Scott L Melideo, Adolfo Mazzeo, Michael Voronkov, Kristen L Huber, Eduardo Pérez, Maxwell Stock, Jeffry B Stock and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Kesava AsamDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.
Agnieszka StaniszewskiDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.
Hong ZhangDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.
Scott L MelideoDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Adolfo MazzeoDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.
Michael VoronkovSignum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America.
Kristen L HuberSignum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America.
Eduardo PérezSignum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America.
Maxwell StockSignum Biosciences, 133 Wall Street, Princeton, New Jersey, United States of America.
Jeffry B StockDepartment of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Ottavio ArancioDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.
Russell E NichollsDepartment of Pathology and Cell Biology, Columbia University, New York, NY, United States of America.ORCID http://orcid.org/0000-0002-8964-574X
Columbia University · USSignum Biosciences (United States) · USPrinceton University · US

Funding

PP2A Dysregulation in the Pathogenesis of alpha-SynucleinopathiesR01NS101134 · NINDS · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI MOURADIAN, M. MARAL, NICHOLLS, RUSSELL E · 2017 to 2021
$2.3M
Synergistic Neuroprotective Mechanisms of Coffee Components in Parkinson's DiseasR01AT006868 · NCCIH · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI MOURADIAN, M. MARAL, STOCK, JEFFRY B · 2012 to 2016
$2.2M
The regulation of beta-amyloid sensitivity and Alzheimer's related impairments by PP2AR01NS092045 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ARANCIO, OTTAVIO, NICHOLLS, RUSSELL E · 2015 to 2019
$1.8M
NCCIH NIH HHS R01 AT006868NINDS NIH HHS R01 NS092045NINDS NIH HHS R01 NS101134
6 · The paper itself

Abstract

Soluble forms of oligomeric beta-amyloid (Aβ) are thought to play a central role in Alzheimer's disease (AD). Transgenic manipulation of methylation of the serine/threonine protein phosphatase, PP2A, was recently shown to alter the sensitivity of mice to AD-related impairments resulting from acute exposure to elevated levels of Aβ. In addition, eicosanoyl-5-hydroxytryptamide (EHT), a naturally occurring component from coffee beans that modulates PP2A methylation, was shown to confer therapeutic benefits in rodent models of AD and Parkinson's disease. Here, we tested the hypothesis that EHT protects animals from the pathological effects of exposure to elevated levels of soluble oligomeric Aβ. We treated mice with EHT-containing food at two different doses and assessed the sensitivity of these animals to Aβ-induced behavioral and electrophysiological impairments. We found that EHT administration protected animals from Aβ-induced cognitive impairments in both a radial-arm water maze and contextual fear conditioning task. We also found that both chronic and acute EHT administration prevented Aβ-induced impairments in long-term potentiation. These data add to the accumulating evidence suggesting that interventions with pharmacological agents, such as EHT, that target PP2A activity may be therapeutically beneficial for AD and other neurological conditions.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCoffeeCognitionCognition DisordersConditioning, PsychologicalDisease Models, AnimalElectrophysiologyFearFemaleLong-Term PotentiationMaleMaze LearningMethylationMiceAmyloid beta-PeptidesCoffeeeicosanoyl-5-hydroxytryptamideSerotonin

Identifiers

PMID29253878
PMCPMC5734769
OpenAlexW2779307554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.